![]() |
|
|
Vol. 300, Issue 1, 236-244, January 2002
Unit of Pharmacology, Institut Municipal d'Investigació
Mèdica (C.H.-L., M.F., P.N.R., E.M., N.P., J.O., J.C., R.T.);
Universitat Autònoma de Barcelona (M.F., P.N.R., R.T.); Unit of
Psychiatry, Hospital del Mar (M.T.), and Universitat Pompeu Fabra,
Barcelona, Spain (J.C.)
3,4-Methylenedioxymethamphetamine (MDMA) is frequently consumed in
association with alcohol. The effect of this combination in humans has
not been previously investigated. Nine male healthy volunteers received
single oral doses of 100 mg of MDMA plus 0.8 g/kg ethanol, 100 mg of
MDMA, 0.8 g/kg of ethanol, and placebo in a double blind, double dummy,
randomized crossover trial. Measurements included psychomotor
performance, subjective effects, and pharmacokinetics. Plasma
concentrations of MDMA showed a 13% increase after the use of alcohol,
whereas plasma concentrations of alcohol showed a 9 to 15% decrease
after MDMA administration. The MDMA-alcohol combination induced longer
lasting euphoria and well being than MDMA or alcohol alone. MDMA
reversed the subjective sedation induced by alcohol but did not reduce
drunkenness feelings. MDMA did not reverse the actions of alcohol on
psychomotor abilities. Combined use of MDMA and alcohol causes
dissociation between subjective and objective sedation. Subjects may
feel euphoric and less sedated and might have the feeling of doing
better, but actual performance ability continues to be impaired by the
effect of alcohol. Confirmation of these findings in further studies
will be highly relevant in terms of road safety.
This article has been cited by other articles:
![]() |
M. Farre, S. Abanades, P. N. Roset, A. M. Peiro, M. Torrens, B. O'Mathuna, M. Segura, and R. de la Torre Pharmacological Interaction between 3,4-Methylenedioxymethamphetamine (Ecstasy) and Paroxetine: Pharmacological Effects and Pharmacokinetics J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 954 - 962. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Parrott MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress J Psychopharmacol, March 1, 2006; 20(2): 147 - 163. [Abstract] [PDF] |
||||
![]() |
G. J. H. Dumont and R. J. Verkes A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers J Psychopharmacol, March 1, 2006; 20(2): 176 - 187. [Abstract] [PDF] |
||||
![]() |
R. Pacifici, S. Pichini, P. Zuccaro, M. Farre, M. Segura, J. Ortuno, S. Di Carlo, A. Bacosi, P. N. Roset, J. Segura, et al. Paroxetine Inhibits Acute Effects of 3,4-Methylenedioxymethamphetamine on the Immune System in Humans J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 285 - 292. [Abstract] [Full Text] |
||||
![]() |
J. R. Oesterheld, S. C. Armstrong, and K. L. Cozza Ecstasy: Pharmacodynamic and Pharmacokinetic Interactions Psychosomatics, February 1, 2004; 45(1): 84 - 87. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Maskalyk Drinking and driving Can. Med. Assoc. J., February 4, 2003; 168(3): 313 - 313. [Full Text] [PDF] |
||||